RESUMO
RATIONALE: Brexpiprazole is a novel serotonin-dopamine activity modulator approved by the USFDA in July 2015 for the treatment of schizophrenia and as an adjunctive therapy with other antidepressants for major depressive disorder in adults. However, limited numbers of metabolites are reported in the literature for brexpiprazole. Our prime intent behind this study is to revisit metabolite profiling of brexpiprazole and to identify and characterize all possible in vitro and in vivo metabolites. METHODS: Firstly, the site of metabolism for brexpiprazole was predicted by a Xenosite web predictor model. Secondly, in vitro metabolite profiling was performed by incubating the drug individually with rat liver microsomes, human liver microsomes and rat S9 fraction at 37°C for 1 h in incubator shaker. Finally, for in vivo metabolite identification, a 50 mg kg-1 dose of brexpiprazole was administered to male Sprague-Dawley rats and the presence of various metabolites was confirmed in rat plasma, urine and feces. RESULTS: The predicted atomic site of metabolism was obtained as a color gradient by the Xenosite web predictor tool and, from this study, probable metabolites were listed. In total, 14 phase I and 2 phase II metabolites were identified and characterized in the in vitro and in vivo matrices using ultra-high-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry (UHPLC/QTOF-MS/MS). The majority of metabolites were found in the sample incubated with human liver microsomes and in rat urine, while in the other matrices only a few metabolites were detected. CONCLUSIONS: All the 16 metabolites were identified and characterized using UHPLC/QTOF-MS/MS. The study revealed that brexpiprazole is metabolized via hydroxylation, glucuronidation, S-oxidation, N-oxidation, dioxidation, oxidative deamination, N-dealkylation, etc.
Assuntos
Antipsicóticos/química , Antipsicóticos/metabolismo , Quinolonas/química , Quinolonas/metabolismo , Tiofenos/química , Tiofenos/metabolismo , Animais , Cromatografia Líquida de Alta Pressão , Simulação por Computador , Humanos , Masculino , Microssomos Hepáticos/metabolismo , Estrutura Molecular , Quinolonas/sangue , Quinolonas/urina , Ratos , Ratos Sprague-Dawley , Espectrometria de Massas em Tandem , Tiofenos/sangue , Tiofenos/urinaRESUMO
Methiopropamine (1-(thiophen-2-yl)-2-methylaminopropane) is a synthetic methamphetamine analogue and is classified as a novel psychoactive substance. The use of novel psychoactive substance has been increasing substantially for recreational purpose in recent years. Methiopropamine was first detected in 2011 in Finland and was later detected in the United Kingdom. It can be purchased on the Internet and is currently poorly regulated. Reported adverse effects of methiopropamine use are mostly anecdotal user reports on Internet forums, and there are limited data on its pharmacodynamics and toxicity in the literature. Death as a direct result from methiopropamine toxicity has not been reported in Australia. We report here the first case of death caused by recreational use of methiopropamine in Australia. This same incident highlights the first ever death from isolated methiopropamine use. Being an analogue of methamphetamine, we hypothesize that the mechanism of death caused by methiopropamine would not be dissimilar to methamphetamine.
Assuntos
Arritmias Cardíacas/induzido quimicamente , Metanfetamina/análogos & derivados , Psicotrópicos/efeitos adversos , Tiofenos/efeitos adversos , Adulto , Transtornos Relacionados ao Uso de Anfetaminas/complicações , Evolução Fatal , Humanos , Masculino , Metanfetamina/efeitos adversos , Metanfetamina/sangue , Metanfetamina/urina , Psicotrópicos/sangue , Psicotrópicos/urina , Tiofenos/sangue , Tiofenos/urinaRESUMO
Canagliflozin is an oral antihyperglycemic agent used for the treatment of type 2 diabetes mellitus. It blocks the reabsorption of glucose in the proximal renal tubule by inhibiting the sodium-glucose cotransporter 2. This article describes the in vivo biotransformation and disposition of canagliflozin after a single oral dose of [(14)C]canagliflozin to intact and bile duct-cannulated (BDC) mice and rats and to intact dogs and humans. Fecal excretion was the primary route of elimination of drug-derived radioactivity in both animals and humans. In BDC mice and rats, most radioactivity was excreted in bile. The extent of radioactivity excreted in urine as a percentage of the administered [(14)C]canagliflozin dose was 1.2%-7.6% in animals and approximately 33% in humans. The primary pathways contributing to the metabolic clearance of canagliflozin were oxidation in animals and direct glucuronidation of canagliflozin in humans. Unchanged canagliflozin was the major component in systemic circulation in all species. In human plasma, two pharmacologically inactive O-glucuronide conjugates of canagliflozin, M5 and M7, represented 19% and 14% of total drug-related exposure and were considered major human metabolites. Plasma concentrations of M5 and M7 in mice and rats from repeated dose safety studies were lower than those in humans given canagliflozin at the maximum recommended dose of 300 mg. However, biliary metabolite profiling in rodents indicated that mouse and rat livers had significant exposure to M5 and M7. Pharmacologic inactivity and high water solubility of M5 and M7 support glucuronidation of canagliflozin as a safe detoxification pathway.
Assuntos
Glucosídeos/metabolismo , Hipoglicemiantes/metabolismo , Tiofenos/metabolismo , Administração Oral , Adulto , Animais , Bile/metabolismo , Canagliflozina , Radioisótopos de Carbono , Cães , Fezes/química , Feminino , Glucosídeos/sangue , Glucosídeos/farmacocinética , Glucosídeos/urina , Glucuronídeos/metabolismo , Humanos , Hipoglicemiantes/sangue , Hipoglicemiantes/farmacocinética , Hipoglicemiantes/urina , Espectroscopia de Ressonância Magnética , Masculino , Camundongos , Pessoa de Meia-Idade , Ratos , Ratos Sprague-Dawley , Especificidade da Espécie , Tiofenos/sangue , Tiofenos/farmacocinética , Tiofenos/urina , Distribuição Tecidual , Adulto JovemRESUMO
Rivaroxaban and dabigatran are new oral anticoagulants (NOACs) that inhibit directly factor Xa and thrombin, respectively. These NOACs effectively prevent thromboembolic complications using fixed doses without the need for dose adjustment according to laboratory results. About 60% of rivaroxaban is cleared from circulation by glomerular filtration, 30% of which is excreted as active drug. About 80% of dabigatran is excreted into urine as active compound. Accordingly, both NOACs can be determined in urine by means of chromatographic methods. Only a few laboratories are able to perform such methods, and results are not available within short time frames. New methods have to be developed to obtain results within minutes and possibly as point-of-care (POC) techniques. This testing may be useful for special patient populations such as those with acute deterioration of renal function due to any disease, before surgical interventions, during unexpected bleeding or thrombotic episodes while on therapy with NOACs, the oldest and youngest populations, pregnancy, suspicion of overdose and intoxication, and to determine adherence to therapy. Here we describe results of a POC qualitative assay using urine samples from patients on treatment with dabigatran and rivaroxaban.
Assuntos
Benzimidazóis/urina , Testes de Química Clínica/métodos , Morfolinas/urina , Tiofenos/urina , beta-Alanina/análogos & derivados , Administração Oral , Anticoagulantes/administração & dosagem , Anticoagulantes/urina , Benzimidazóis/administração & dosagem , Dabigatrana , Inibidores do Fator Xa , Feminino , Humanos , Masculino , Morfolinas/administração & dosagem , Sistemas Automatizados de Assistência Junto ao Leito , Gravidez , Reprodutibilidade dos Testes , Rivaroxabana , Tiofenos/administração & dosagem , beta-Alanina/administração & dosagem , beta-Alanina/urinaRESUMO
2-Methiopropamine [1-(thiophen-2-yl)-2-methylaminopropane, 2-MPA], a thiophene analogue of methamphetamine, is available from online vendors selling "research chemicals." The first samples were seized by the German police in 2011. As it is a recreational stimulant, its inclusion in routine drug screening protocols should be required. The aims of this study were to identify the phase I and II metabolites of 2-MPA in rat and human urine and to identify the human cytochrome-P450 (CYP) isoenzymes involved in its phase I metabolism. In addition, the detectability of 2-MPA in urine samples using the authors' well-established gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-linear ion trap-mass spectrometry (LC-MS(n)) screening protocols was also evaluated. The metabolites were isolated from rat and human urine samples by solid-phase extraction without or following enzymatic cleavage of conjugates. The phase I metabolites, following acetylation, were separated and identified by GC-MS and/or liquid chromatography-high-resolution linear ion trap mass spectrometry (LC-HR-MS(n)) and the phase II metabolites by LC-HR-MS(n). The following major metabolic pathways were proposed: N-demethylation, hydroxylation at the side chain and at the thiophene ring, and combination of these transformations followed by glucuronidation and/or sulfation. CYP1A2, CYP2C19, CYP2D6, and CYP3A4 were identified as the major phase I metabolizing enzymes. They were also involved in the N-demethylation of the analogue methamphetamine and CYP2C19, CYP2D6, and CYP3A4 in its ring hydroxylation. Following the administration of a typical user's dose, 2-MPA and its metabolites were identified in rat urine using the authors' GC-MS and the LC-MS(n) screening approaches. Ingestion of 2-MPA could also be detected by both protocols in an authentic human urine sample.
Assuntos
Cromatografia Líquida/métodos , Cromatografia Gasosa-Espectrometria de Massas/métodos , Metanfetamina/urina , Tiofenos/urina , Animais , Sistema Enzimático do Citocromo P-450/metabolismo , Humanos , Masculino , Metanfetamina/análogos & derivados , Metanfetamina/metabolismo , Ratos , Ratos Wistar , Tiofenos/química , Tiofenos/metabolismoRESUMO
The derivatives of 1,2-dithiolane are scattered widely throughout the natural world where they are generally exploited for their biocidal properties. One of these, known as asparagusic acid (1,2-dithiolane-4-carboxylic acid), is present in the frequently consumed vegetable, asparagus, and though apparently innocuous toxicologically, it may be responsible for the distinctive urine odor produced after consuming this food. This review collects together, for the first time, historical observations associating asparagus ingestion with this unique odor-producing phenomenon and collates data implicating a 1,2-dithiolane structure as the major chemical precursor responsible.
Assuntos
Asparagus/química , Botânica/história , Odorantes/análise , Tiofenos/análise , Urina/química , Dieta , História Antiga , Humanos , Tiofenos/urinaRESUMO
We have considered the urinary excretion profile of methiopropamine (MPA), a thiophene ring-based structural analog of methamphetamine with similar stimulant effects, with the aim of selecting the most appropriate marker(s) of intake that may be useful in forensic analysis. For this purpose, in vitro studies were preliminarily performed on human liver microsomes for tracing the phase I metabolic pathways of MPA, preselecting the best candidates as potential target analytes, and designing the optimal experimental strategy. In vivo studies were then conducted on mice, after the intraperitoneal administration of a 10-mg/kg dose. Urine samples were collected every 3 h in the first 9 h and, subsequently, from 24 to 36 h, and stored at -80°C until further analysis. The measurements were performed using a targeted procedure based on liquid/liquid extraction followed by liquid chromatography-tandem mass spectrometry analysis. Our results show that in the time interval 0-9 h after administration, MPA was extensively oxidized mainly to nor-MPA, oxo-MPA, and two hydroxylated metabolites (ie, hydroxy-aryl-methiopropamine and hydroxy-alkyl-methiopropamine). All phase I metabolites underwent phase II metabolism, with the formation of nor-hydroxy-methiopropamine only in phase II, confirmed by the results obtained after enzymatic hydrolysis with ß-glucuronidase and arylsulfatase. In the time interval 24-36 h after administration, only unchanged MPA and nor-MPA were detected, suggesting that these two markers are those endowed with the highest diagnostic value. The method was validated for these two principal markers, proving to be fit for anti-doping, toxicological, and forensic analyses.
Assuntos
Metanfetamina/análogos & derivados , Tiofenos/urina , Animais , Estimulantes do Sistema Nervoso Central/administração & dosagem , Estimulantes do Sistema Nervoso Central/urina , Cromatografia Líquida , Drogas Desenhadas/administração & dosagem , Drogas Desenhadas/análise , Drogas Ilícitas/urina , Infusões Parenterais , Masculino , Metanfetamina/administração & dosagem , Metanfetamina/urina , Camundongos , Camundongos Endogâmicos ICR , Detecção do Abuso de Substâncias , Espectrometria de Massas em Tandem , Tiofenos/administração & dosagemRESUMO
Over the past few decades, colorimetric assays have been developed for cost-effective and rapid on-site urinalysis. Most of these assays were employed for detection of biomarkers such as glucose, uric acid, ions, and albumin that are abundant in urine at micromolar to millimolar levels. In contrast, direct assaying of urinary biomarkers such as glycated proteins, low-molecular-weight reactive oxygen species, and nucleic acids that are present at significantly lower levels (nanomolar to picomolar) remain challenging due to the interferences from the urine sample matrix. State-of-the-art assays for detection of trace amounts of urinary biomarkers typically utilize time-consuming and equipment-dependent sample pretreatment or clean-up protocols prior to assaying, which limits their applicability for on-site analysis. Herein, we report a colorimetric assay for on-site detection of trace amount of generic biomarkers in urine without involving tedious sample pretreatment protocols. The detection strategy is based on monitoring the changes in optical properties of poly(3-(4-methyl-3'-thienyloxy)propyltriethylammonium bromide) upon interacting with an aptamer or a peptide nucleic acid in the presence and absence of target biomarkers of relevance for the diagnosis of metabolic complications and diabetes. As a proof of concept, this study demonstrates facile assaying of advanced glycation end products, 8-hydroxy-2'-deoxyguanosine and hepatitis B virus DNA in urine samples at clinically relevant concentrations, with limits of detection of â¼850 pM, â¼650 pM, and â¼ 1 nM, respectively. These analytes represent three distinct classes of biomarkers: (i) glycated proteins, (ii) low-molecular-weight reactive oxygen species, and (iii) nucleic acids. Hence, the proposed methodology is applicable for rapid detection of generic biomarkers in urine, without involving sophisticated equipment and skilled personnel, thereby enabling on-site urinalysis. At the end of the contribution, we discuss the opportunity to translate the homogeneous assay into a paper-based format.
Assuntos
Biomarcadores/urina , Técnicas Biossensoriais/métodos , Colorimetria/métodos , Humanos , Limite de Detecção , Polímeros , Tiofenos/urina , UrináliseRESUMO
The dopamine agonist rotigotine was developed for the treatment of Parkinson's disease and restless legs syndrome. Disposition, metabolism, elimination, and absolute bioavailability of rotigotine were determined in six healthy male subjects by using two different forms of administration in a randomized sequence with a crossover design. Treatment A (continuous infusion) consisted of a single radiolabeled 12-h intravenous infusion of 1.2 mg of rotigotine (0.6 mg of [(14)C] and 0.6 mg of unlabeled rotigotine, 3.7 MBq) solution. Treatment B (transdermal application) consisted of a single 10-cm(2) patch containing 4.5 mg of unlabeled rotigotine with a patch-on period of 24 h. During the 12 h-infusion, total radioactivity concentration rapidly increased within 2 h; there was a slight additional increase toward the end of infusion. Plasma concentrations of total radioactivity declined by 75% within 12 h after completion of infusion. More than 94% of the radioactivity was excreted 216 h after the start of infusion, 71% by the kidneys and 23% by feces. Renal elimination of the parent compound was <1%. Systemically absorbed rotigotine was rapidly metabolized. The major rotigotine biotransformation pathway was conjugation of the parent compound, mainly by sulfation; a second pathway was the formation of phase 1 metabolites (N-desalkylation) with subsequent conjugation. Plasma concentration-time profiles of unchanged rotigotine during and after infusion and during and after patch administration were comparable. Absolute bioavailability of transdermally applied rotigotine was 37%.
Assuntos
Absorção/efeitos dos fármacos , Administração Cutânea , Agonistas de Dopamina/farmacocinética , Infusões Intravenosas/métodos , Tetra-Hidronaftalenos/farmacocinética , Tiofenos/farmacocinética , Absorção/fisiologia , Adolescente , Adulto , Disponibilidade Biológica , Estudos Cross-Over , Agonistas de Dopamina/sangue , Agonistas de Dopamina/metabolismo , Agonistas de Dopamina/urina , Humanos , Masculino , Pessoa de Meia-Idade , Tetra-Hidronaftalenos/sangue , Tetra-Hidronaftalenos/metabolismo , Tetra-Hidronaftalenos/urina , Tiofenos/sangue , Tiofenos/metabolismo , Tiofenos/urina , Adulto JovemRESUMO
In this work, an SPE-HPLC method coupled to photodiode array detection was validated in human urine matrix, in order to monitor four antihypertensive angiotensin II receptor antagonist drugs in patients under cardiovascular treatment. For that purpose, experimental design was used. Quantitation was accomplished by the internal standard method. The obtained LOQs were 95, 113, 125, and 85 ng/mL for eprosartan, telmisartan, irbesartan, and valsartan, respectively. The intraday and interday precision and accuracy at four concentration levels in the working range (LOQ-15 microg/mL) were always lower than 11% RSD and 8% relative error. The urine samples proved to be stable during 4 h at room temperature, after three thaw-freeze cycles, and for 2 months at -20 degrees C. No interferences from other endogenous compounds or co-administered drugs were found. The method has been successfully applied to monitor the renal elimination of eprosartan and valsartan during 24 h.
Assuntos
Bloqueadores do Receptor Tipo 1 de Angiotensina II/urina , Antagonistas de Receptores de Angiotensina , Anti-Hipertensivos/urina , Extração em Fase Sólida/métodos , Acrilatos/análise , Acrilatos/isolamento & purificação , Acrilatos/urina , Idoso , Idoso de 80 Anos ou mais , Bloqueadores do Receptor Tipo 1 de Angiotensina II/análise , Bloqueadores do Receptor Tipo 1 de Angiotensina II/isolamento & purificação , Anti-Hipertensivos/análise , Anti-Hipertensivos/isolamento & purificação , Benzimidazóis/análise , Benzimidazóis/isolamento & purificação , Benzimidazóis/urina , Benzoatos/análise , Benzoatos/isolamento & purificação , Benzoatos/urina , Compostos de Bifenilo/análise , Compostos de Bifenilo/isolamento & purificação , Compostos de Bifenilo/urina , Cromatografia Líquida de Alta Pressão/instrumentação , Cromatografia Líquida de Alta Pressão/métodos , Feminino , Humanos , Imidazóis/análise , Imidazóis/isolamento & purificação , Imidazóis/urina , Irbesartana , Masculino , Pessoa de Meia-Idade , Extração em Fase Sólida/instrumentação , Telmisartan , Tetrazóis/análise , Tetrazóis/isolamento & purificação , Tetrazóis/urina , Tiofenos/análise , Tiofenos/isolamento & purificação , Tiofenos/urina , Valina/análogos & derivados , Valina/análise , Valina/isolamento & purificação , Valina/urina , ValsartanaRESUMO
AIM: Hemay005 is a novel small-molecule inhibitor of phosphodiesterase-4 developed for the treatment of psoriasis. Measurement of Hemay005 in biological samples is critical for evaluation of its pharmacokinetics in clinical studies. Methodology & results: Plasma and urine samples were extracted and then chromatographed on an Acquity UPLC HSS T3 column with a gradient elution. Detection was performed on a Xevo TQ-S tandem mass spectrometer using negative ESI. CONCLUSION: For the first time, a sensitive and robust ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was established and validated for the quantitative determination of Hemay005 in human plasma and urine, and it was successfully applied to evaluate the pharmacokinetics of Hemay005 in healthy subjects in a first-in-human study.
Assuntos
Acetamidas/sangue , Acetamidas/urina , Análise Química do Sangue/métodos , Cromatografia Líquida de Alta Pressão/métodos , Pirróis/sangue , Pirróis/urina , Espectrometria de Massas em Tandem/métodos , Tiofenos/sangue , Tiofenos/urina , Urinálise/métodos , Acetamidas/farmacocinética , Métodos Analíticos de Preparação de Amostras , Humanos , Inibidores da Fosfodiesterase 4/sangue , Inibidores da Fosfodiesterase 4/farmacocinética , Inibidores da Fosfodiesterase 4/urina , Pirróis/farmacocinética , Reprodutibilidade dos Testes , Tiofenos/farmacocinéticaRESUMO
The reactions involved in the metabolic pathways of SR9009 were characterized by liquid chromatography-mass spectrometry (LC-MS) to identify the most appropriate marker(s) of use. The effects of gender, genetic polymorphism, and drug-drug interaction on the metabolic profile of SR9009 were also evaluated. In vitro approaches were based on the use of human liver microsomes and cytochrome P450 isoforms. Sample preparation included an enzymatic hydrolysis (performed only for the phase II investigation) followed by liquid-liquid extraction. The chromatographic separation was carried out using a reverse-phase column; detection was performed by either a triple-quadrupole or a time-of-flight system in positive electrospray ionization and different acquisition modes. In the presence of human liver microsomes, SR9009 was biotransformed to 13 metabolites by CYP3A4, CYP3A5, CYP2C19, and CYP2D6 isoenzymes. The reactions included hydroxylation, de-alkylation, oxidation, and combinations thereof, the de-alkylated metabolites being the most abundant. Once formed the mentioned metabolites underwent glucuronidation. Concerning the effects of gender, genetic polymorphism, and drug-drug interaction on the metabolic profile of SR9009, our observation have shown the following: (a) No significant alterations were measured between female and male, (b) significant differences were registered using either the CYP2D6 or CYP2C19 allelic variants, and finally (c) significant alterations were registered in the presence of ketoconazole, miconazole, fluoxetine, nefazodone and paroxetine; moderate variation were instead registered with fluconazole, itraconazole, gestodene, and levonorgestrel. This observation put in evidence the importance to take into account both genetic polymorphism and drug-drug interaction to select the most appropriate marker(s) of use in doping analysis.
Assuntos
Metaboloma , Microssomos Hepáticos/metabolismo , Membro 1 do Grupo D da Subfamília 1 de Receptores Nucleares/agonistas , Pirrolidinas/metabolismo , Tiofenos/metabolismo , Cromatografia Líquida de Alta Pressão/métodos , Sistema Enzimático do Citocromo P-450/genética , Sistema Enzimático do Citocromo P-450/metabolismo , Interações Medicamentosas , Feminino , Humanos , Masculino , Polimorfismo Genético , Pirrolidinas/urina , Espectrometria de Massas em Tandem/métodos , Tiofenos/urinaRESUMO
A protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method has been developed and validated for the determination of eprosartan in human plasma and urine. The solvent system also served as a protein precipitation reagent. The chromatographic separation was achieved on a CAPCELL PAK C18 column (50 mmx2.0 mm, 5 microm, Shiseido). A mobile phase was consisted of 0.5% formic acid in water and 0.5% formic acid in acetonitrile (72:28). Detection was by positive ion electrospray tandem mass spectrometry on a Sciex API3000. The standard curves, which ranged from 5 to 2000 ng/mL in human plasma and from 0.25 to 50 microg/mL in urine, were fitted to a 1/x weighted quadratic regression model. The method proved to be accurate, specific and sensitive enough to be successfully applied to a pharmacokinetic study.
Assuntos
Acrilatos/sangue , Acrilatos/urina , Cromatografia Líquida/métodos , Imidazóis/sangue , Imidazóis/urina , Espectrometria de Massas em Tandem/métodos , Tiofenos/sangue , Tiofenos/urina , Acrilatos/química , Humanos , Imidazóis/química , Estrutura Molecular , Reprodutibilidade dos Testes , Tiofenos/químicaRESUMO
The study aims to evaluate the pharmacokinetics and urinary excretion of eprosartan in Chinese healthy volunteers and to study the effect of gender on pharmacokinetics of eprosartan. Twenty healthy volunteers (ten men and ten women) were recruited for an open trial and received a single dose of 600 mg eprosartan. Using a validated LC/MS/MS method, plasma and urinary concentrations of eprosartan were determined. The following pharmacokinetic parameters were elucidated after administration: the area under the plasma concentration versus time curve from 0 to 32 h (AUC0-32h) 14818.75 +/- 7312.11 ng x h/mL, the area under the plasma concentration versus time curve from 0 to infinite (AUC(0-infinity)) 15081.62 +/- 7379.63 ng x h/mL, peak plasma concentration (Cmax) 3664.25 x 1653.94 ng x h/mL, time to Cmax (Tmax) 1.63 +/- 0.46 h, elimination half-life (t(1/2)) 8.03 +/- 4.04 h, apparent clearance (CL/F) 47.84 +/- 19.21 L/h, apparent volume of distribution of the central compartment (V/F) 537.21 +/- 287.91 L, renal clearance (CLr) 1.33 +/- 0.41 L/h, amount of unchanged eprosartan excreted into urine 18.44 +/- 6.43 mg and fraction of unchanged eprosartan excreted into urine 3.07 +/- 1.07%. Our results also indicated that no gender differences were observed in the pharmacokinetics of eprosartan in Chinese healthy volunteers.
Assuntos
Acrilatos/farmacocinética , Anti-Hipertensivos/farmacocinética , Imidazóis/farmacocinética , Tiofenos/farmacocinética , Acrilatos/urina , Adulto , Anti-Hipertensivos/urina , Área Sob a Curva , Eletrocardiografia , Feminino , Meia-Vida , Humanos , Imidazóis/urina , Masculino , Caracteres Sexuais , Tiofenos/urinaRESUMO
BACKGROUND: Little or no pharmacological or toxicological data are available for novel psychoactive substances when they first emerge, making their identification and interpretation in biological matrices challenging. MATERIALS & METHODS: A new synthetic cathinone, α-pyrrolidinopentiothiophenone (α-PVT), was incubated with hepatocytes and samples were analyzed using liquid chromatography coupled to a Q Exactive™ Orbitrap mass spectrometer. Authentic urine specimens from suspected α-PVT cases were also analyzed. Scans were data mined with Compound Discoverer™ for identification and structural elucidation of metabolites. RESULTS/CONCLUSION: Seven α-PVT metabolites were identified in hepatocyte incubations, and in the authentic urine samples, also with an additional monohydroxylated product and a glucuronide of low intensity. α-PVT dihydroxypyrrolidinyl, α-PVT 2-ketopyrrolidinyl, α-PVT hydroxythiophenyl and α-PVT thiophenol had the most intense in vivo signals.
Assuntos
Estimulantes do Sistema Nervoso Central/metabolismo , Simulação por Computador , Metabolômica/métodos , Pirrolidinas/metabolismo , Tiofenos/metabolismo , Estimulantes do Sistema Nervoso Central/urina , Mineração de Dados , Hepatócitos/metabolismo , Humanos , Espectrometria de Massas , Microssomos Hepáticos/metabolismo , Pirrolidinas/urina , Tiofenos/urinaRESUMO
Use of methiopropamine (MPA), a synthetic metamfetamine analog, has been detected since 2011 in Europe, but there is limited information on its acute toxicity. A 30-year-old man was admitted to the emergency department in a confused state, with paranoid delusion, auditory and visual hallucinatory experiences, and incoherent speech following the use of "synthacaine" (a slang term derived from "synthetic" and "cocaine"). Toxicological screening for pharmaceuticals and drugs of abuse by liquid chromatography-diode-array detector, gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry (LC-MS-MS) detected MPA, which was subsequently quantified by a specific LC-MS-MS method. Of note, 13 h after presentation to the emergency department, the plasma concentration of MPA was 14 ng/mL. This case report confirms the toxicity of MPA and the need for toxicological analysis to confirm the substance actually ingested by users of new psychoactive substances.
Assuntos
Drogas Ilícitas/toxicidade , Metanfetamina/análogos & derivados , Metanfetamina/toxicidade , Transtornos Relacionados ao Uso de Substâncias/metabolismo , Tiofenos/toxicidade , Calibragem , Cromatografia Líquida de Alta Pressão/métodos , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Drogas Ilícitas/sangue , Drogas Ilícitas/urina , Imunoensaio , Extração Líquido-Líquido , Masculino , Metanfetamina/sangue , Metanfetamina/urina , Espectrometria de Massas por Ionização por Electrospray , Transtornos Relacionados ao Uso de Substâncias/sangue , Transtornos Relacionados ao Uso de Substâncias/urina , Espectrometria de Massas em Tandem , Tiofenos/sangue , Tiofenos/urinaRESUMO
The aim of this study was to examine the efficacy and safety of duloxetine, a balanced and potent dual reuptake inhibitor of serotonin and norepinephrine, in the management of diabetic peripheral neuropathic pain. Serotonin and norepinephrine are thought to inhibit pain via descending pain pathways. In a 12-week, multicenter, double-blind study, 457 patients experiencing pain due to polyneuropathy caused by Type 1 or Type 2 diabetes mellitus were randomly assigned to treatment with duloxetine 20 mg/d (20 mg QD), 60 mg/d (60 mg QD), 120 mg/d (60 mg BID), or placebo. The diagnosis was confirmed by a score of at least 3 on the Michigan Neuropathy Screening Instrument. The primary efficacy measure was the weekly mean score of the 24-h Average Pain Score, which was rated on an 11-point (0-10) Likert scale (no pain to worst possible pain) and computed from diary scores between two site visits. Duloxetine 60 and 120 mg/d demonstrated statistically significant greater improvement compared with placebo on the 24-h Average Pain Score, beginning 1 week after randomization and continuing through the 12-week trial. Duloxetine also separated from placebo on nearly all the secondary measures including health-related outcome measures. Significantly more patients in all three active-treatment groups achieved a 50% reduction in the 24-h Average Pain Score compared with placebo. Duloxetine treatment was considered to be safe and well tolerated with less than 20 percent discontinuation due to adverse events. Duloxetine at 60 and 120 mg/d was safe and effective in the management of diabetic peripheral neuropathic pain.
Assuntos
Neuropatias Diabéticas/tratamento farmacológico , Placebos/uso terapêutico , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , Tiofenos/uso terapêutico , Idoso , Demografia , Depressão/tratamento farmacológico , Depressão/etiologia , Neuropatias Diabéticas/sangue , Neuropatias Diabéticas/complicações , Neuropatias Diabéticas/urina , Relação Dose-Resposta a Droga , Método Duplo-Cego , Cloridrato de Duloxetina , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Medição da Dor/efeitos dos fármacos , Medição da Dor/métodos , Inventário de Personalidade , Inibidores Seletivos de Recaptação de Serotonina/sangue , Inibidores Seletivos de Recaptação de Serotonina/urina , Tiofenos/sangue , Tiofenos/urina , Resultado do TratamentoRESUMO
A rapid, sensitive and high-throughput ultra-performance liquid chromatography method with tandem mass spectrometry (UPLC-MS/MS) has been developed for the determination of DAT-230 in rat plasma, urine, feces and tissues (heart, liver, spleen, lung, kidney, stomach, intestine and brain). The biological samples were prepared by protein precipitation, and separation was achieved on an ACQUITY™ UPLC BEH C18 column (50 mm × 2.1mm, 1.7 µm) with a mobile phase that consisted of methanol - 0.2% formic acid water (80:20, v/v) at a flow rate of 0.2 mL/min. The MS/MS ion transitions were monitored at m/z 372.17 â 357.17 for DAT-230 and m/z 406.08 â 345.16 for COH-203 (internal standard, IS). The calibration curve was linear in the range of 0.1-5200 ng/mL for all biological matrices (r(2) ≥ 0.996), and it had the same value for the lower limit of quantification. The validated method was successfully applied to the pharmacokinetics, tissue distribution and excretion study after intravenous administration of a 5mg/kg dose of DAT-230 to healthy Sprague-Dawley rats. The mean pharmacokinetic parameters of t1/2 and AUC0-12 were (1.1 ± 0.4)h and (861.0 ± 281.2) ng h/mL, respectively. Tissue distribution results indicated that DAT-230 exhibited rapid distribution and high liver, kidney, spleen, stomach and intestine uptake; these organs were indicated as the major target organs of the drug. In total, 5.3% of the administered DAT-230 was excreted in an unconverted form in urine, feces and bile, which implies that DAT-230 was excreted primarily in the form of metabolites.
Assuntos
Compostos de Anilina/farmacocinética , Cromatografia Líquida/métodos , Eliminação Hepatobiliar , Ensaios de Triagem em Larga Escala , Eliminação Intestinal , Eliminação Renal , Espectrometria de Massas em Tandem/métodos , Tiofenos/farmacocinética , Moduladores de Tubulina/farmacocinética , Compostos de Anilina/administração & dosagem , Compostos de Anilina/sangue , Compostos de Anilina/urina , Animais , Área Sob a Curva , Bile/metabolismo , Biotransformação , Calibragem , Cromatografia Líquida/normas , Fezes/química , Meia-Vida , Ensaios de Triagem em Larga Escala/normas , Injeções Intravenosas , Modelos Lineares , Masculino , Taxa de Depuração Metabólica , Ratos Sprague-Dawley , Padrões de Referência , Reprodutibilidade dos Testes , Espectrometria de Massas em Tandem/normas , Tiofenos/administração & dosagem , Tiofenos/sangue , Tiofenos/urina , Distribuição Tecidual , Moduladores de Tubulina/administração & dosagem , Moduladores de Tubulina/sangue , Moduladores de Tubulina/urinaRESUMO
Potential systemic effects of the racemic carbonic anhydrase inhibitor MK-927 and its S-enantiomer, sezolamide hydrochloride, after topical ocular administration were investigated in a double-masked, randomized, placebo-controlled study in 16 healthy volunteers. A controlled diet was started 4 days before initiation of treatment and continued throughout the study. For 14 days six volunteers received bilaterally one drop of 2% MK-927 (1.2 mg) q.i.d., six received one drop of 1.8% sezolamide (1.1 mg) q.i.d., and four received the common vehicle q.i.d. Blood and urine electrolytes and acid-base profiles were measured before and on days 1, 7, and 14 of treatment, and 24-hour urine samples were collected daily. All values were compared with those on the pretreatment day. Taking the circadian variations of the parameters into account, no significant treatment effect was observed in either the daily profiles or the 14-day cumulative sodium, potassium, and citrate excretions. Because the usual variability of the measured biologic parameters has been reduced markedly by the stringent requirements of this study, it can be concluded that the induction of clinically significant metabolic changes by topically administered MK-927 or sezolamide is unlikely.
Assuntos
Inibidores da Anidrase Carbônica/farmacologia , Sulfonamidas/farmacologia , Tiofenos/farmacologia , Administração Tópica , Adulto , Pressão Sanguínea/efeitos dos fármacos , Inibidores da Anidrase Carbônica/sangue , Inibidores da Anidrase Carbônica/urina , Eletrocardiografia/efeitos dos fármacos , Eletrólitos/urina , Olho , Frequência Cardíaca/efeitos dos fármacos , Humanos , Concentração de Íons de Hidrogênio , Rim/metabolismo , Masculino , Soluções Oftálmicas , Sulfonamidas/sangue , Sulfonamidas/urina , Tiofenos/sangue , Tiofenos/urinaRESUMO
A sensitive GLC assay for ticrynafen, a diuretic agent with uricosuric properties, and its two metabolites in urine, serum, and plasma is described. The method employs methylation of carboxylic acid groups and trimethylsilyation of the hydroxyl group on one metabolite that cannot otherwise be separated readily from ticrynafen as a simple methyl ester. Urinary output and serum or plasma levels of ticrynafen and its two metabolites were measured in specimens from human volunteers receiving one 250-mg tablet.